Clinical response of azithromycin as an adjunct to non-surgical periodontal therapy in smokers

Journal of Periodontology

Volumn 76, Issue 3, 2005, Pages 426-436

  Mascarenhas, Paulo ^a   Gapski, Ricardo ^a,b   Al Shammari, Khalaf ^a,c   Hill, Roger ^a   Soehren, Stephen ^a   Fenno, J Christopher ^a   Giannobile, William V ^a   Wang, Hom Lay ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c MINISTRY OF HEALTH   (Kuwait)

Author keywords

Azithromycin therapeutic use; Comparison studies; Periodontitis drug therapy; Periodontitis therapy; Planing; Scaling; Smoking adverse effects

Indexed keywords

AZITHROMYCIN; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1;

ADULT; AGED; ARTICLE; BIOASSAY; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG UTILIZATION; FEMALE; GINGIVA BLEEDING; GINGIVITIS; HUMAN; LABORATORY TEST; MALE; MOUTH EXAMINATION; PERIODONTAL DISEASE; PERIODONTICS; PREVALENCE; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BENZOYLARGININE-2-NAPHTHYLAMIDE; CHRONIC DISEASE; DENTAL SCALING; FEMALE; FOLLOW-UP STUDIES; GINGIVAL CREVICULAR FLUID; GINGIVAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL POCKET; PERIODONTITIS; PROCOLLAGEN; ROOT PLANING; SINGLE-BLIND METHOD; SMOKING; TREATMENT OUTCOME;

EID: 18744397538     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.3.426     Document Type: Article

References (86)

1. Lindhe J, Nyman S. The effect of plaque control and surgical pocket elimination on the establishment and maintenance of periodontal health. A longitudinal study of periodontal therapy in cases of advanced disease. J Clin Periodontol 1975;2:67-79.
2. Hill RW, Ramfjord SP, Morrison EC, et al. Four types of periodontal treatment compared over two years. J Periodontol 1981;52:655-662.
3. Ramfjord SP, Caffesse RG, Morrison EC, et al. Four modalities of periodontal treatment compared over five years. J Periodontal Res 1987;22:222-223.
4. Caffesse RG, Sweeney PL, Smith BA. Scaling and root planing with and without periodontal flap surgery. J Clin Periodontol 1986;13:205-210.
5. Rabbani GM, Ash MM Jr, Caffesse RG. The effectiveness of subgingival scaling and root planing in calculus removal. J Periodontol 1981;52:119-123.
6. Becker W, Becker BE, Caffesse R, et al. A longitudinal study comparing scaling, osseous surgery, and modified Widman procedures: Results after 5 years. J Periodontol 2001;72:1675-1684.
7. Knowles JW, Burgett FG, Nissle RR, et al. Results of periodontal treatment related to pocket depth and attachment level. Eight years. J Periodontol 1979;50:225-233.
8. Scabbia A, Cho KS, Sigurdsson TJ, et al. Cigarette smoking negatively affects healing response following flap debridement surgery. J Periodontol 2001;72:43-49.
9. Preber H, Bergstrom J. Effect of cigarette smoking on periodontal healing following surgical therapy. J Clin Periodontol 1990;17:324-328.
10. Preber H, Bergstrom J. The effect of non-surgical treatment on periodontal pockets in smokers and non-smokers. J Clin Periodontol 1986;13:319-323.
11. Grossi SG, Genco RJ, Machtei EE, et al. Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. J Periodontol 1995;66:23-29.
12. Haber J, Wattles J, Crowley M, et al. Evidence for cigarette smoking as a major risk factor for periodontitis. J Periodontol 1993;64:16-23.
13. Haffajee AD, Socransky SS. Relationship of cigarette smoking to attachment level profiles. J Clin Periodontol 2001;28:283-295.
14. Haffajee AD, Socransky SS. Relationship of cigarette smoking to the subgingival microbiota. J Clin Periodontol 2001;28:377-388.
15. Zambon JJ, Grossi SG, Machtei EE, et al. Cigarette smoking increases the risk for subgingival infection with periodontal pathogens. J Periodontol 1996;67(Suppl.): 1050-1054.
16. Ah MK, Johnson GK, Kaldahl WB, et al. The effect of smoking on the response to periodontal therapy. J Clin Periodontol 1994;21:91-97.
17. Preber H, Bergstrom J. Occurrence of gingival bleeding in smoker and non-smoker patients. Acta Odontol Scand 1985; 43:315-320.
18. Bain CA, Moy PK. The association between the failure of dental implants and cigarette smoking. Int J Oral Maxillofac Implants 1993;3:609-615.
19. Haffajee AD, Cugini MA, Dibart S, et al. The effect of SRP on the clinical and microbiological parameters of periodontal diseases. J Clin Periodontol 1997;24:324-34.
20. American Academy of Periodontology. Tobacco use and the periodontal patient (position paper). J Periodontol 1999;70:1419-1427.
21. Tonetti MS. Cigarette smoking and periodontal diseases: Etiology and management of disease. Ann Periodontol 1998;3:88-101.
22. Kaldahl WB, Johnson GK, Patil KD, et al. Levels of cigarette consumption and response to periodontal therapy. J Periodontol 1996;67:675-681.
23. Costabel U, Bross KJ, Reuter C, et al. Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. Chest 1986;90:39-44.
24. MacFarlane GD, Herzberg MC, Wolff LF, et al. Refractory periodontitis associated with abnormal polymorphonuclear leukocyte phagocytosis and cigarette smoking. J Periodontol 1992;63:908-913.
25. Johnson JD, Houchens DP, Kluwe WM, et al. Effects of mainstream and environmental tobacco smoke on the immune system in animals and humans: A review. Crit Rev Toxicol 1990;20:369-395.
26. Loesche WJ, Gusberti F, Mettraux G, et al. Relationship between oxygen tension and subgingival bacterial flora in untreated human periodontal pockets. Infect Immun 1983;42:659-667.
27. Mettraux GR, Gusberti FA, Graf H. Oxygen tension (pO2) in untreated human periodontal pockets. J Periodontol 1984; 55:516-521.
28. Venditto MA. Therapeutic considerations: Lower respiratory tract infections in smokers. J Am Osteopath Assoc 1992;92:897-900;903-905.
29. Silverstein P. Smoking and wound healing. Am J Med 1992;93:22S-24S.
30. Raulin LA, McPherson JC 3rd, McQuade MJ, et al. The effect of nicotine on the attachment of human fibroblasts to glass and human root surfaces in vitro. J Periodontol 1988;59:318-325.
31. Hanes PJ, Schuster GS, Lubas S. Binding, uptake, and release of nicotine by human gingival fibroblasts. J Periodontol 1991;62:147-152.
32. Badersten A, Nilveus R, Egelberg J. Effect of nonsurgical periodontal therapy. III. Single versus repeated instrumentation. J Clin Periodontol 1984;11:114-124.
33. Hirschfeld L, Wasserman B. A long-term survey of tooth loss in 600 treated periodontal patients. J Periodontol 1978; 49:225-237.
34. McFall WT Jr. Tooth loss in 100 treated patients with periodontal disease. A long-term study. J Periodontol 1982;53:539-549.
35. Haffajee AD, Socransky SS, Ebersole JL. Survival analysis of periodontal sites before and after periodontal therapy. J Clin Periodontol 1985;12:553-567.
36. Magnusson I, Clark WB, Low SB, et al. Effect of non-surgical periodontal therapy combined with adjunctive antibiotics in subjects with "refractory" periodontal disease. (I). Clinical results. J Clin Periodontol 1989;16:647-653.
37. Colombo AP, Haffajee AD, Dewhirst FE, et al. Clinical and microbiological features of refractory periodontitis subjects. J Clin Periodontol 1998;25:169-180.
38. Kleinfelder JW, Muller RF, Lange DE. Bacterial susceptibility to amoxicillin and potassium clavulanate in advanced periodontitis patients not responding to mechanical therapy. J Clin Periodontol 2000;27:846-853.
39. Levy RM, Giannobile WV, Feres M, et al. The effect of apically repositioned flap surgery on clinical parameters and the composition of the subgingival microbiota: 12-month data. Int J Periodontics Restorative Dent 2002;22:209-219.
40. Magnusson I, Marks RG, Clark WB, et al. Clinical, microbiological and immunological characteristics of subjects with "refractory" periodontal disease. J Clin Periodontol 1991;18:291-299.
41. Loesche WJ, Syed SA, Morrison EC, et al. Metronidazole in periodontitis. I. Clinical and bacteriological results after 15 to 30 weeks. J Periodontol 1984;55:325-335.
42. Collins JG, Offenbacher S, Arnold RR. Effects of a combination therapy to eliminate Porphyromonas gingivalis in refractory periodontitis. J Periodontol 1993;64:998-1007.
43. Socransky SS, Haffajee AD. The bacterial etiology of destructive periodontal disease: Current concepts. J Periodontol 1992;63(Suppl.):322-331.
44. Socransky SS, Haffajee AD, Cugini MA, et al. Microbial complexes in subgingival plaque. J Clin Periodontol 1998;25:134-144.
45. Slots J, van Winkelhoff AJ. Antimicrobial therapy in periodontics. J Calif Dent Assoc 1993;21:51-56.
46. Drisko CH. Non-surgical pocket therapy: Pharmacotherapeutics. Ann Periodontol 1996;1:491-566.
47. Hanes PJ, Purvis JP. Local anti-infective therapy: Pharmacological agents. A systematic review. Ann Periodontol 2003;8:79-98.
48. Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-infective therapy: Pharmacological agents. A systematic review. Ann Periodontol 2003;8:115-181.
49. Sanz M, Herrera D. Antibiotic and Antimicrobial Use in Dental Practice, 2nd ed. Chicago: Quintessence Books; 2001:33-52.
50. Sefton AM, Maskell JP, Beighton D, et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol 1996;23:998-1003.
51. Pajukanta R, Asikainen S, Saarela M, et al. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1992;36:1241-1243.
52. Pajukanta R. In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol 1993;8:325-326.
53. Powers JL. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Pediatr Infect Dis J 1996;15 (Suppl. 9):S30-S37.
54. Gladue RP, Bright GM, Isaacson RE, et al. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-282.
55. Filatova NA, Kuznetsov EA, Dmitrieva LA, et al. The prospects for using the new macrolide antibiotic azithromycin (Sumamed) in the combined treatment of periodontitis (in Russian). Stomatologiia 1995;74:12-15.
56. Loesche WJ, Kazor CE, Taylor GW. The optimization of the BANA test as a screening instrument for gingivitis among subjects seeking dental treatment. J Clin Periodontol 1997;24:718-726.
57. Giannobile WV, Lynch SE, Denmark RG, et al. Crevicular fluid osteocalcin and pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. A pilot study in beagle dogs. J Clin Periodontol 1995;22:903-910.
58. Varvara G, D'Arcangelo C. The evaluation of the clinical efficacy and tolerance of azithromycin in odontostomatological infections. Minerva Stomatol 1998;47:57-62.
59. Sasaki J, Kaneko A, Karakida K, et al. Comparative clinical study of azithromycin with tosufloxacin tosilate in the treatment of acute odontogenic infection. Jpn J Antibiot 1995;48:1093-1118.
60. Malizia T, Batoni G, Ghelardi E, et al. Interaction between piroxicam and azithromycin during distribution to human periodontal tissues. J Periodontol 2001;72:1151-1156.
61. Malizia T, Tejada MR, Ghelardi E, et al. Periodontal tissue disposition of azithromycin. J Periodontol 1997;68:1206-1209.
62. Stein GE, Havlichek DH. The new macrolide antibiotics. Azithromycin and clarithromycin. Postgrad Med 1992;92: 269-272;277-282.
63. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl. A):73-82.
64. Rodriguez-Bano J, Pascoal A, Ballesta S, et al. Penetration of azithromycin in human neutrophils: Influence in production of hydrogen peroxide (in Spanish). Enferm Infecc Microbiol Clin 1997;15:196-199.
65. McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991;10: 828-33.
66. Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis 1991; 10:807-812.
67. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990;34:1056-1060.
68. Wildfeuer A, Laufen H, Muller-Wening D, et al. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. Arzneimittelforschung 1989;39: 755-758.
69. Raulston JE. Pharmacokinetics of azithromycin and erythromycin in human endometrial epithelial cells and in cells infected with Chlamydia trachomatis. J Antimicrob Chemother 1994; 34:765-776.
70. Ballow CH, Amsden GW. Azithromycin: The first azalide antibiotic. Ann Pharmacother 1992;26:1253-1261.
71. Baughman RP, DeSante KA, Lanier TL, et al. The penetration of dirithromycin into bronchoalveolar lavage fluid and alveolar macrophages. J Antimicrob Chemother 1994;33:1045-1050.
72. Mor N, Vanderkolk J, Heifets L. Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. Pharmacotherapy 1994;14:100-104.
73. Kaldahl WB, Kalkwarf KL, Patil KD, et al. Evaluation of four modalities of periodontal therapy. Mean probing depth, probing attachment level, and recession changes. J Periodontol 1988;59:783-793.
74. Badersten A, Nilveus R, Egelberg J. Effect of nonsurgical periodontal therapy. II. Severely advanced periodontitis. J Clin Periodontol 1984;11:63-76.
75. Hammerle CH, Joss A, Lang NP. Short-term effects of initial periodontal therapy (hygienic phase). J Clin Periodontol 1991;18:233-239.
76. Morrison EC, Ramfjord SP, Hill RW. Short-term effects of initial, nonsurgical periodontal treatment (hygienic phase). J Clin Periodontol 1980;7:199-211.
77. Claffey N, Loos B, Gantes B, et al. The relative effects of therapy and periodontal disease on loss of probing attachment after root debridement. J Clin Periodontol 1988;15:163-169.
78. Palmer RM, Matthews JP, Wilson RF. Non-surgical periodontal treatment with and without adjunctive metronidazole in smokers and non-smokers. J Clin Periodontol 1999;26:158-163.
79. Blandizzi C, Malizia T, Lupetti A, et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol 1999;70:960-966.
80. Slots J, Mashimo P, Levine MJ, et al. Periodontal therapy in humans. I. Microbiological and clinical effects of a single course of periodontal scaling and root planing, and of adjunctive tetracycline therapy. J Periodontol 1979;50: 495-509.
81. Sbordone L, Ramaglia L, Gulletta E, et al. Recolonization of the subgingival microflora after scaling and root planing in human periodontitis. J Periodontol 1990;61:579-584.
82. Lavanchy DL, Bickel M, Baehni PC. The effect of plaque control after scaling and root planing on the subgingival microflora in human periodontitis. J Clin Periodontol 1987;14:295-299.
83. Al-Shammari KF, Giannobile WV, Aldredge WA, et al. Effect of non-surgical periodontal therapy on C-telopeptide pyridinoline cross-links (ICTP) and interleukin-1 levels. J Periodontol 2001;72:1045-1051.
84. Grossi SG, Skrepcinski FB, DeCaro T, et al. Response to periodontal therapy in diabetics and smokers. J Periodontol 1996;67(Suppl.):1094-1102.
85. Preber H, Linder L, Bergstrom J. Periodontal healing and periopathogenic microflora in smokers and non-smokers. J Clin Periodontol 1995;22:946-952.
86. Palys MD, Haffajee AD, Socransky SS, Giannobile WV. Relationship between C-telopeptide pyridinoline cross-links (ICTP) and putative periodontal pathogens in periodontitis. J Clin Periodontol 1998;25:865-871.